We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+18.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$635M
AUM Growth
-$6.52M
(-1%)
Cap. Flow
-$38.5M
Cap. Flow
% of AUM
-6.06%
Top 10 Holdings %
Top 10 Hldgs %
52.93%
Holding
70
New
19
Increased
8
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$47.3M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$17.4M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$14.1M |
| 4 |
ADMA Biologics
ADMA
|
+$12.6M |
| 5 |
Dentsply Sirona
XRAY
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$33.8M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$19.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$18.7M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$16M |
| 5 |
AngioDynamics
ANGO
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$2.25B
| $53.1M | 8.36% |
4,146,605
+3,233,618
| +354% | +$47.3M |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $50.3M | 7.92% |
1,020,178
-423,770
| -29% | -$16M |
|
|
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $43.6M | 6.86% |
1,494,520
-162,200
| -10% | -$5.01M |
|
|
ADMS
4
DELISTED
Adamas Pharmaceuticals
ADMS
| $36.6M | 5.76% |
1,417,121
+281,918
| +25% | +$7.81M |
|
|
CORI
5
DELISTED
Corium International, Inc.
CORI
| $28.8M | 4.54% |
3,597,057
+477,412
| +15% | +$4.52M |
|
6
Travere Therapeutics
TVTX
$5.17B
| $28.6M | 4.5% |
1,048,693
-129,533
| -11% | -$3.45M |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $27.5M | 4.33% |
622,380
+85,000
| +16% | +$3.5M |
|
|
ENDP
8
DELISTED
Endo International plc
ENDP
| $24.4M | 3.85% |
+2,591,573
| New | +$17.4M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $22.2M | 3.49% |
1,339,575
-1,224,600
| -48% | -$18.7M |
|
|
CPRX
10
DELISTED
Catalyst Pharmaceutical
CPRX
| $21.1M | 3.33% |
6,772,764
-40,000
| -0.6% | -$121K |
|
|
11
Heron Therapeutics
HRTX
$89.9M
| $20.2M | 3.18% |
519,787
-1,061,629
| -67% | -$33.8M |
|
|
PETX
12
DELISTED
Aratana Therapeutics, Inc.
PETX
| $18.3M | 2.87% |
4,294,426
| – | – |
|
|
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
| $16.7M | 2.63% |
2,724,663
+100,000
| +4% | +$702K |
|
|
EXAS
14
DELISTED
Exact Sciences
EXAS
| $15.6M | 2.46% |
+261,400
| New | +$14.1M |
|
|
ZGNX
15
PUT
DELISTED
Zogenix, Inc.
ZGNX
| $14.8M | 2.33% |
+335,000
| New | +$13.8M |
|
|
16
ADMA Biologics
ADMA
$2.02B
| $14.7M | 2.31% |
3,249,829
+2,529,300
| +351% | +$12.6M |
|
|
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
| $14M | 2.21% |
2,340,649
-453,103
| -16% | -$3.32M |
|
|
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $12.6M | 1.99% |
4,278,819
| – | – |
|
19
Tandem Diabetes Care
TNDM
$1.21B
| $12.6M | 1.98% |
+570,598
| New | +$7.02M |
|
|
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
| $11.9M | 1.88% |
4,623,247
-50,000
| -1% | -$124K |
|
|
21
Dentsply Sirona
XRAY
$2.73B
| $11.5M | 1.81% |
+262,900
| New | +$12.3M |
|
|
ENDP
22
CALL
DELISTED
Endo International plc
ENDP
| $11.3M | 1.78% |
+1,200,000
| New | +$8.07M |
|
23
Integra LifeSciences
IART
$1.48B
| $10.5M | 1.66% |
163,424
-135,000
| -45% | -$8.36M |
|
|
TLGT
24
DELISTED
Teligent, Inc
TLGT
| $10.4M | 1.63% |
299,982
+130,903
| +77% | +$4.12M |
|
|
SCTL
25
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $10.3M | 1.62% |
2,283,548
-209,620
| -8% | -$1.66M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Broadfin Capital held 70 positions worth $635M, down 1% from $642M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Broadfin Capital withdrew a net $38.5M in Q2 2018, closing 25 positions and reducing 12 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $19.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.
Against the trend, Broadfin Capital opened a new position in Endo International plc worth $24.4M.
- Broadfin Capital's largest Q2 2018 buy was Endo International plc: 2,591,573 shares worth $24.4M.
- Broadfin Capital added most to Iovance Biotherapeutics in Q2 2018, an estimated $47.3M increase.
- Broadfin Capital's biggest Q2 2018 reduction was Heron Therapeutics, cutting an estimated $33.8M.
- Broadfin Capital fully exited GW Pharmaceuticals Plc American Depositary Shares in Q2 2018, selling an estimated $19.7M.
- Broadfin Capital's ten largest holdings make up 53% of its $635M portfolio in Q2 2018.
- Broadfin Capital opened 19 new positions and closed 25 in Q2 2018.
- Broadfin Capital's portfolio value fell 1% quarter-over-quarter to $635M.
Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.